Vanguard Capital Management’s Starling Oncology STLN Stock Holding History
Bought
Maintained
Sold
Other funds holding STLN
JAIC
Vanguard Capital Management's STLN Position: Q3 2026 in Review
Vanguard Capital Management increased its Starling Oncology (STLN) stake by 6.3% in Q3 2026, buying an estimated $1.23M and bringing the position to 3,471,514 shares worth $21.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2348.
Vanguard Capital Management first reported a position in STLN in Q1 2026 and has held it in 3 quarters since. 130 funds tracked by Wall St. Rank hold STLN as of Q3 2026.
- Vanguard Capital Management held 3,471,514 shares of Starling Oncology worth $21.9M as of Q3 2026.
- Vanguard Capital Management bought 205,983 Starling Oncology shares in Q3 2026, an estimated $1.23M.
- Starling Oncology made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #2348 holding.
- Vanguard Capital Management first reported a position in Starling Oncology in Q1 2026 and has held it in 3 quarters since.
- 130 funds tracked by Wall St. Rank held Starling Oncology as of Q3 2026.
Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.